期刊名称：ANNALS OF PHARMACOTHERAPY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Now in its 44th year, The Annals is an independent, peer-reviewed medical journal that advances pharmacotherapy throughout the world by publishing evidence-based articles on practice and research. The Annals provides an independent forum for the discussion and analysis of professional issues in pharmacotherapy. To fulfill its mission, The Annals will:
|
• |
publish research reports, reviews, commentaries, case reports, and other articles that are of high quality, unique, and timely and that will advance patient care and clinical pharmacy practice. |
| |
|
• |
provide service that is personal, professional, and prompt to authors, reviewers, and subscribers, surpassing their expectations and building ongoing relationships. |
| |
|
• |
maintain an editorial board and referee base of skilled, dedicated clinicians, researchers, and educators with collective expertise in all areas of pharmacy. |
| |
|
• |
keep abreast of the latest developments in publishing and information technology, adopting those deemed most likely to enhance the journal’s content and services. |
| |
With this focus, The Annals of Pharmacotherapy will continually strive to improve clinical practice and patient care worldwide.
Staff
| Publisher |
| Harvey AK Whitney, Jr. MSPharm, Publisher |
| Deborah S Hyrne, Publisher's Assistant |
Instructions to Authors
|
Submission should be made at The Annals' manuscript submission page. Upload the manuscript and cover letter in a format compatible with Microsoft Word for Windows. Combine title page, abstract, text, references, and table(s) into a single document prior to online submission. Art (eg, figures, photographs) must be computer-generated or scanned in high resolution (see also "Figures"). Each figure should be submitted as a separate electronic file. The Author Signature Form and other applicable documents (see "Other Considerations for Manuscript Submission") must be mailed to the Editorial Office within 10 days of manuscript submission. If online submission is not possible, a diskette or CD containing the cover letter, manuscript, and any figures must be mailed to the Editorial Office. Other applicable documents, as described above, must also be included. |
|
Cover letter. All cover letters must include the following:
- Name of corresponding author with full mailing address, telephone and fax numbers, and email address;
- Article category preference (see "Article Categories");
- Brief explanation of the topic's significance to patient care;
- Explanation about any similar work by the author(s) or data from the same study that is under review or in press, or results previously presented or published (see "Duplicate Publication");
- Request for anonymity during peer review, if desired (see also "Title Page");
|
|
Author Signature Form
The Author Signature form, containing Assignment of Copyright, Criteria for Authorship, and Acknowledgment, must be signed by each author and received by The Annals within 10 days of manuscript submission. Original signatures of all authors are required; faxed, photocopied, or scanned signatures are not acceptable. |
|
Assignment of Copyright
Authors must transfer all rights, title, and interest to their manuscript to Harvey Whitney Books Company, publisher of The Annals of Pharmacotherapy. |
|
Criteria for Authorship
Authorship criteria are identical to those spelled out in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Specifically, authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3. Assistance solely in nonsubstantive aspects of the submission, for example, the acquisition of funding, assembly of data, and referral of patients, does not justify authorship. At least one author must be responsible for each section of the manuscript. |
|
Acknowledgment
Persons who have contributed significantly to the substance of the paper, but whose contributions do not justify authorship, should be acknowledged. Acknowledgment of technical writers must include their sources of funding. Authors must ensure that all persons named in the acknowledgment, excluding those providing financial or technical support, have agreed in writing to be named. |
| OTHER CONSIDERATIONS FOR MANUSCRIPT SUBMISSION |
|
Permission to use copyrighted material: Written permission (original stamp/signature) from the publisher, organization, or person who holds copyright is necessary for use of previously published tables, figures, or other copyrighted material. |
|
Informed consent: Identifying information should not be present in written descriptions or photographs of persons unless considered essential for scientific purposes. In such cases, written informed consent from the person must be obtained by the authors, with documentation included with manuscript submission. |
|
Manuscript Checklist Form: This form must be completed and submitted within 10 days of manuscript submission. |
|
Duplicate publication: Work that has been published or is described in an article submitted for publication elsewhere may not warrant further consideration. It is the corresponding author's responsibility to inform the editor about all submissions and previous reports describing the same work. |
|
Rapid publication: If requested, justification of need should be provided. |
|
Conflict of interest statement: Authors must report any conflicts of interest, including consulting fees, paid expert testimony, employment, grants, honoraria, patents, royalties, stocks, or any other relationships or ethical considerations that may involve the subject matter of the manuscript and compromise its integrity. If there are no conflicts, authors should make a statement of this fact. |
Expanded article category guidelines are also available from the Editorial Office. |
|
Research Reports: Original research involving medication effectiveness, safety, pharmacoeconomics, pharmacokinetics, pharmacogenomics, interactions, adherence and use, and pharmacy practice. Meta-analyses are also considered research. Well-designed prospective studies are given highest priority for acceptance. Limitations of studies must be stated in the text. All reports must include, when applicable, a statement in the Methods section that the work was conducted in compliance with Institutional Review Board/Human Subjects Research Committee requirements. |
|
Review Articles: Comprehensive, significant, critical, and analytical reviews that include essential information on a well-delineated subject. Some articles are selected for The Annals' continuing education program (PharmaCE), for which the author provides a goal, objectives, and questions according to guidelines available from the Editorial Office. Reviews must synthesize and critically evaluate available data rather than simply describing the findings. Access detailed Review Article guidelines here. Articles are classified using the subcategories below:
|
|
Case Reports: New or unusual events in one or more patients that expand the knowledge about common disease states or provide significant information about drug safety, adverse reactions, or interactions. Clinical and laboratory data and concurrent medications or diseases should be documented. Case reports describing adverse events should adhere to the International Society for Pharmacoepidemiology and International Society of Pharmacovigilance's Guidelines for submitting adverse event reports for publication (Pharmacoepidemiol Drug Saf 2007;16:581-7. DOI 10.1002/pds.1399). Before submitting a report of an adverse drug reaction, the Naranjo ADR probability scale (Clin Pharmacol Ther 1981;30:239-45) or other validated and appropriate scale should be used to assess the likelihood that the events were drug-related. Likewise, for reports of drug interactions, the DIPS scale (Ann Pharmacother 2007;41:674-80. DOI 10.1345/aph.1H423) or another validated scale should be applied. Ranking from the scale must be included in both abstract and text. Priority is given to cases for which the scores indicate a probable or definite association. |
|
Special Contributions: Articles on unusual, topical, or historical subjects that are of unique interest or importance. Contact the Editorial Office prior to submission. |
|
International Reports: Research, reviews, or reports on pharmacy practice and health care that are specific to countries other than the US. |
|
Commentaries: Viewpoints on diverse, controversial, or topical subjects. Access detailed Commentary guidelines here. Contact the Editorial Office prior to submission. |
|
Letters and Comments: Letters and comments should address areas related to clinical practice, research, or education, including recently published articles. Letters are limited to no more than five authors. In cases where adverse effects or drug interactions are described, the Naranjo ADR probability scale or DIPS scale, respectively, should be used to determine the likelihood that the adverse effect was drug-related (see "Case Reports"). Comments must be submitted within 6 months of an article's publication. |
|
Authors are required to follow The Annals' style, which is consistent with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Other useful style references are the American Medical Association Manual of Style; Scientific Style and Format: The CSE Manual for Authors, Editors and Publishers; and The Chicago Manual of Style. |
|
Manuscript Preparation: Manuscripts should be prepared using a 12-point font (Times, not Times New Roman, is preferred) on 8.5 x 11.0 inch (216 x 279 mm) paper (ISO A4 also acceptable), with margins of at least 1 inch (25 mm). All copy should be double-spaced, including title page, abstract, text, acknowledgments, references, tables, and figure legends. Pages must be numbered. |
|
Title Page: The title page should contain:
- Article title (concise, but indicating main focus of paper);
- Name of each author as it should appear in print;
- Highest academic degree, position title, and/or academic appointment of each author;
- Names of departments and institutions with which each author is affiliated;
- Name, address, telephone and fax numbers, and email address of corresponding author;
- Name, address, fax number, and email address of author to whom reprint requests should be sent, if different from corresponding author;
- Statement pertaining to funding and conflict of interest (see "Conflict of Interest Statement");
- Information about presentation of the work as an abstract or poster, if applicable;
- Separate word counts of abstract and main text; and
- Key words for purposes of indexing and searching.
Authors desiring anonymity during peer review must request this in the cover letter and provide a second copy of the manuscript with all identifying information removed and a title page with only items 1, 7, 8, 9, and 10. |
|
Structured Abstract: Abstracts should be no more than 300 words. See structured abstract examples and guidelines online or abstracts in any recent issue of the journal for examples of proper abstract subheadings and content for each article category. Reference citations are not used in the abstract. |
|
Text: Appropriate headings and subheadings should be used liberally throughout the text. Abbreviations must be defined upon first use in the text. Use of abbreviations should be limited to, for example, lengthy terms; the majority of drug names should not be abbreviated. USANs or, when appropriate, chemical names, must be used for all drugs. Manufacturers' code numbers should be used only when a generic name is not yet available. Trade names should be included only to distinguish between different trade preparations, for some combination drugs, or in reviews of drugs that have been recently approved by the FDA. |
|
References: All references, including those related primarily to figures and tables, must appear in the text and be cited consecutively. References in text, tables, and figure legends should be denoted with superscript Arabic numerals. Personal communications (ie, unpublished data) may not be used as numbered references. Information obtained through personal communication must be inserted in parentheses within the text and include the contact person's name, academic degree, affiliation, and date of communication. Signed permission letters from quoted sources indicating the content of the personal communication must be provided to the Editorial Office. Abstracts and Letters to the Editor may be used as numbered references but must be identified as such in the citations. Inclusive pagination must be provided for all references. Journal names should be abbreviated as they appear in PubMed. Those not appearing in PubMed should be spelled out. Referenced articles that are cited as "In press" must include the title of the journal that has accepted the paper. List all authors when there are 6 or fewer; with 7 or more authors, list the first 3, followed by et al. To facilitate online retrieval of references, include a citation's digital object identifier (DOI) if available. More information about DOIs can be obtained at www.crossref.org or dx.doi.org. When citing articles that have been published online prior to print, authors are encouraged to include the date published online (Epub date) in addition to the full print information. When the article has appeared in print, the URL will not be used; however, a DOI should be included if available. Examples of correct referencing style are given below.
- ARTICLE
Baldwin DS, Heldbo Reines E, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 2007;41:1583-92. Epub 11 Sept 2007. DOI 10.1345/aph.1K089
- ARTICLE WITH URL
Centers for Disease Control and Prevention. Strongyloidiasis. www.dpd.cdc.gov/dpdx/HTML/Strongyloidiasis.htm (accessed 2007 Aug 17).
- ABSTRACT
Rao N, Knebel W, Bergsma T, et al. Population pharmacokinetics of istradefylline (abstract 13). J Clin Pharmacol 2007;47:1185.
- JOURNAL SUPPLEMENT
Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation executive summary: Joint American College of Chest Physicians/American Association of Cardiovascular and Pulmonary Rehabilitation Evidence-Based Clinical Practice Guidelines. Chest 2007;131(suppl):1S-3S. DOI 10.1378/chest.07-0892
- JOURNAL OR MAGAZINE PAGINATED BY ISSUE
Vyzral K. Legislative update. Ohio Pharmacist 2007;56(9):17.
- BOOK CHAPTER
Shah M, Cunningham MJ. Toxicogenomics. In: Gad SC, ed. Handbook of pharmaceutical biotechnology. 1st ed. Hoboken, NJ: John Wiley & Sons, Inc., 2007:229-51.
- PACKAGE INSERT
Product information. Zantac (ranitidine). Research Triangle Park, NC: GlaxoSmithKline, June 2007.
- SCIENTIFIC PRESENTATION
Davis TM, Yeap B, Bruce DG, Davis WA. Lipid-lowering therapy protects against peripheral sensory neuropathy in type 2 diabetes. Presented at: 67th Scientific Sessions. American Diabetes Association Annual Meeting, Chicago, IL, June 22, 2007.
- MONOGRAPH IN ELECTRONIC FORMAT
Tamoxifen. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex, expires 2007 Dec 31 (accessed 2007 Jan 11).
|
|
Appendices: When necessary, appendices should be used to present lengthy or detailed surveys, descriptions of extensive mathematical calculations, and/or itemized lists. They should be placed (with legends as needed) following the reference list in the manuscript. Lengthy appendices, such as algorithms, surveys, and protocols, will be published only online; the URL will be provided in the printed article where the appendix is cited. |
|
Tables: Each table must be double-spaced on a separate page. A brief title must be provided for each table. Each column requires a brief descriptive heading. Explanations and full terms for abbreviations used should appear alphabetically below the body of table. Statistical measures of variation (ie, standard deviation) should be identified in footnotes (designated as a, b, c, etc.). The units of measure used for all data in a column should be indicated. Internal horizontal or vertical rules should not be used. Duplication of table content within text should be minimized. |
|
Figures: Figures should be computer generated, photographed, or professionally drawn and submitted as a PDF (photographs 300 dpi; line art 1200 dpi). Original hard copies or electronic files are required; photocopies are not acceptable. Each figure should be provided as a separate page or electronic file. Figures generated in PowerPoint, as well as freehand or with typewritten lettering, are unacceptable. Send an electronic version of each figure or 2 sharp, glossy originals of photographs; sharp laser copies of line art are acceptable. Letters, numbers, and symbols should be clear, uniform in size, and large and dark enough to be legible when the size of the figure is reduced to fit column width in the journal. Titles and detailed explanations should appear in the legends rather than in the figures. Bar graphs or pie charts should be in black and white only and not contain gray shading as filler or background; distinctive fillings should be used instead (eg, white or solid black; horizontal, vertical, or slanted stripes; cross-hatching; dots). Dotted lines and decimal points should be dark enough to reproduce well. Background horizontal or vertical lines should not be used. Figures should have labels on their margins or backs indicating file number, figure number, and corresponding author’s name at top of figure. The top of a figure should also be designated on the back if the figure lacks distinguishing features. Legends should be double-spaced, and each abbreviation and symbol used must be defined. Duplication of figure content within text should be minimized. |
Instructions to Authors
a1060-0280.pdf
Editorial Board
|
ADVERSE REACTIONS AND MEDICATION SAFETY
Hedva Barenholtz Levy PharmD BCPS CGP, St. Louis, MO, Chairman
Catherine Christen PharmD, Ann Arbor, MI
Ron MC Herings PharmD PhD, Utrecht, The Netherlands
Esther-Lee Marcus MD, Jerusalem, Israel
ALLERGY
Kathryn V Blake PharmD, Jacksonville, FL, Chairman
Sandra R Knowles BScPharm, Toronto, Ontario
ALZHEIMER'S DISEASE
Todd P Semla PharmD MS BCPS FCCP, Evanston, IL, Chairman
Jeanette M Cavano PharmD, San Francisco, CA
Ellie S Elliott PharmD BCPP, Shawnee Mission, KS
Carlos H Rojas-Fernandez PharmD BCPP, Washington, DC
John J Sramek PharmD, Glendale, CA
AMBULATORY CARE
Christopher M Terpening PhD PharmD, Charleston, WV, Chairman
Melissa M Blair PharmD BCPS CDE, Charleston, SC
Joaquim Bonal PhD, Barcelona, Spain
Barry L Carter PharmD FCCP FAHA BCPS, Iowa City, IA
Susan E Fugate PharmD BCPS CACP, Oklahoma City, OK
ANTICOAGULATION
William E Dager PharmD FCSHP, Sacramento, CA, Chairman
Maureen A Smythe PharmD FCCP, Detroit, MI
Gordon J Vanscoy PharmD CACP MBA, Pittsburgh, PA
Thomas G Vondracek PharmD BCPS, Denver, CO
ASTHMA
H William Kelly PharmD BCPS, Albuquerque, NM, Chairman
Debora Schotik Chan BSPharm PharmD FASHP, Honolulu, HI
Mary E Teresi PharmD, Iowa City, IA
BIOINFORMATICS
Ronald A Herman PhD, Iowa City, IA, Chairman
Marie A Abate PharmD, Morgantown, WV
Lisa M Deziel-Evans PharmD PhD, Fort Lauderdale, FL
J Daniel Robinson PharmD, Gainesville, FL
CARDIOLOGY
Patricia A Howard PharmD FCCP BCPS, Kansas City, KS, Chairman
Judy WM Cheng PharmD BCPS, Brooklyn, NY
Vincent J Colucci PharmD BCPS, Missoula, MT
Michael A Crouch PharmD BCPS, Richmond, VA
James S Kalus PharmD BCPS, Detroit, MI
Vincent F Mauro PharmD FCCP, Toledo, OH
Mark A Munger PharmD FCCP, Salt Lake City, UT
Jean M Nappi PharmD FCCP BCPS, Charleston, SC
Paolo Raggi MD FACC, New Orleans, LA
Sarah A Spinler PharmD FCCP, Philadelphia, PA
CLINICAL PHARMACEUTICS
Lawrence A Trissel BS Pharm FASHP, Houston, TX, Chairman
Kathy Dudley Webster PharmD PhD, Buies Creek, NC
CLINICAL PHARMACOLOGY
Gideon Koren MD FABMT FRCPC, Toronto, Ontario, Chairman
Iain LO Buxton PharmD FAHA, Reno, NV
Cynthia A Carnes PharmD PhD, Columbus, OH
Thomas YK Chan MBChB MD PhD FRCP, Hong Kong, China
CLINICAL SERVICES AND FORMULARY MANAGEMENT
Patricia L Forrester BSPharm PharmD, Flint, MI, Chairman
Wendy E Gay PharmD, Troy, MI
Aixa M Rey PharmD, North Miami Beach, FL
Marisel Segarra-Newnham PharmD MPH BCPS, West Palm Beach, FL
CLINICAL TRIALS
Suzanne Jones PharmD, Nashville, TN, Chairman
John B Leslie MD, Scottsdale, AZ
Marc Levine PhD, Vancouver, BC
Sharon M Watling PharmD BCPS, Ann Arbor, MI
COMPLEMENTARY AND ALTERNATIVE MEDICINE
Mary L Chavez PharmD, Glendale, AZ, Chairman
Donal P O'Mathuna PhD, Dublin, Ireland
Kelly M Shields PharmD, Ada, OH
CRITICAL CARE
John W Devlin PharmD BCPS FCCM, Boston, MA, Chairman
Robert E Ariano PharmD BCPS, Winnipeg, Manitoba
Michael J Cawley PharmD RRT CPFT, Philadelphia, PA
Joseph F Dasta MS, Columbus, OH
Brian L Erstad PharmD FCCM FASHP, Tucson, AZ
Salmaan Kanji PharmD, Ottawa, Ontario
Laurie S Mauro PharmD, Toledo, OH
DEMENTIA
Jeffrey C Delafuente MS FCCP FASCP, Richmond, VA, Chairman
Joseph T Hanlon PharmD MS, Minneapolis, MN
Sandra G Jue PharmD FASHP, Boise, ID
Alessandro Nobili MD, Milan, Italy
DERMATOLOGY
Franklin P Flowers MD, Gainesville, FL, Chairman
Ai Young Lee MD PhD, Seoul, Korea
DIABETES
R Keith Campbell BPharm MBA CDE, Pullman, WA, Chairman
Brian K Irons PharmD BCPS, Lubbock, TX
Linda A Jaber PharmD, Detroit, MI
Lisa A Kroon PharmD CDE, San Francisco, CA
DRUG, ALCOHOL, AND SUBSTANCE ABUSE
Paul L Doering MS, Gainesville, FL, Chairman
S Casey Laizure PharmD, Memphis, TN
Margaret A Medicus-Bringa BSPharm, Milwaukee, WI
Agnes Vass MD, Jerusalem, Israel
DRUG INFORMATION
Dennis F Thompson PharmD FASHP FCCP, Oklahoma City, OK, Chairman
Mary Lea Gora-Harper PharmD, Lexington, KY
Randy C Hatton PharmD FCCP BCPS, Gainesville, FL
Nancy Schuddekopf Jordan PharmD BCPS, Holyoke, MA
Mike Kendrach PharmD, Birmingham, AL
Denise R Kockler PharmD, Richmond, VA
Amy Heck Sheehan PharmD, Indianapolis, IN
DRUG INTERACTIONS
Lisa Ellen Davis PharmD, Philadelphia, PA, Chairman
Kenneth A Bachmann PhD FCP, Toledo, OH
Edward A Hartshorn PhD, Galveston, TX
DYSLIPIDEMIA
Matthew K Ito PharmD FCCP BCPS, Stockton, CA, Chairman
Abdulrazaq S Al-Jazairi PharmD, Riyadh, Saudi Arabia
Kathleen O Hagmeyer PharmD BCPS, Toledo, OH
Pamela Louise Stamm BS PharmD, Auburn, AL
Julie Wright PharmD FCCP BCPS, Kansas City, MO
EMERGENCY AND TRAUMA MEDICINE
Lisa Denise Burry BScPharm PharmD FCCP, Toronto, ON, Chairman
Edward C Dillon Jr BScBA BScPharm PharmD, New Westminster, BC
Michael J Rieder MD PhD FRCPC, London, ON
Peter J Zed BSc BSc(Pharm) PharmD, Vancouver, BC
ENDOCRINOLOGY
Mary E Elliott PharmD PhD, Madison, WI, Chairman
Susyn Lynn Plushner PharmD BCPS, Denver, CO
EPILEPSY
James W McAuley PhD, Columbus, OH, Chairman
William R Garnett PharmD FCCP, Richmond, VA
Michael D Privitera MD, Cincinnati, OH
Bradley V Vaughn MD, Chapel Hill, NC
EVIDENCE-BASED PRACTICE
Kimi S Vesta PharmD BCPS, Oklahoma City, OK, Chairman
Jill S Burkiewicz PharmD BCPS, Downers Grove, IL
Anne L Hume PharmD FCCP BCPS, Kingston, RI
FAMILY MEDICINE
Charles D Ponte PharmD CDE BCPS BC-ADM, Morgantown, WV, Chairman
Debbie C Byrd PharmD BCPS, Auburn, AL
Rex W Force PharmD FCCP BCPS, Pocatello, ID
Barry J Gales PharmD, Oklahoma City, OK
John G Gums PharmD, Gainesville, FL
Kelly W Jones PharmD BCPS, Florence, SC
Mark E Jones PharmD, Davenport, IA
FORENSIC MEDICINE
Mitchell Marsh PharmD BCPS, Lincoln, NE, Chairman
Robert J Belloto BSPharm PhD CGP FASCP, Cincinnati, OH
Peter D Frade PhD, Detroit, MI
Frank P Paloucek BS PharmD ABAT, Chicago, IL
GASTROENTEROLOGY
Pramodini B Kale-Pradhan PharmD, Detroit, MI, Chairman
William R Bartle PharmD FCSHP, Toronto, ON
Paul W Jungnickel MS PhD, Auburn, AL
GERIATRICS AND LONG-TERM CARE
Shelly L Gray PharmD MS BCPS, Seattle, WA, Chairman
Margaret B Artz BSPharm PhD, Minneapolis, MN
Catherine A Heyneman PharmD MS CGP FASCP, Pocatello, ID
Lisa J Miller BS PharmD BCPP CGP, Houston, TX
Patricia L Orlando PharmD, Salt Lake City, UT
HEMATOLOGY
Robert D Christensen MD, St. Petersburg, FL, Chairman
Gerald M Higa PharmD BCOP, Morgantown, WV
Kristi L Lenz PharmD, Charleston, SC
Paul E Monahan MD, Chapel Hill, NC
HOSPICE AND PALLIATIVE CARE
David P Elliott PharmD FCCP, Charleston, WV, Chairman
Debra K Farver PharmD, Yankton, SD
Robert K Sylvester PharmD, Fargo, ND
HYPERTENSION
C Michael White PharmD, Storrs, CT, Chairman
James D Coyle PharmD, Columbus, OH
Mark A Gales PharmD BCPS, Weatherford, OK
Stephanie F Gardner PharmD EdD, Little Rock, AR
Larry M Lopez PharmD FCCP, Gainesville, FL
IMMUNOLOGY
Colonel John D Grabenstein PhD FASHP FAPhA, Falls Church, VA, Chairman
Mary S Hayney PharmD BCPS FCCP, Madison, WI
Felix Mor MD PhD, Petah-Tikva, Israel
INFECTIOUS DISEASES
Guy W Amsden PharmD FCP, Cooperstown, NY, Chairman
John D Cleary PharmD FCCP, Jackson, MS
B Joseph Guglielmo PharmD, San Francisco, CA
Daniel P Healy PharmD FCCP, Cincinnati, OH
Daniel R Hinthorn MD FACP, Kansas City, KS
Ben M Lomaestro PharmD, Albany, NY
Steven J Martin PharmD BCPS FCCM, Toledo, OH
David E Nix PharmD, Tucson, AZ
Manjunath P Pai PharmD, Albuquerque, NM
Charles A Peloquin PharmD, Denver, CO
Robert P Rapp PharmD FCCP, Lexington, KY
George G Zhanel PharmD PhD, Winnipeg, Manitoba
INTERNAL MEDICINE
A Scott Mathis PharmD, Piscataway, NJ, Chairman
Donald F Brophy PharmD FCCP BCPS, Richmond, VA
Margaret M Chrymko PharmD, Erie, PA
John A Dougherty MBA PharmD, Orlando, FL
James C Garrelts PharmD, Wichita, KS
Roy C Parish PharmD BCPS, Shreveport, LA
Michael P Rivey MS BCPS, Missoula, MT
Janice L Stumpf PharmD, Ann Arbor, MI
Charles T Taylor PharmD BCPS, Auburn, AL
LABORATORY MEDICINE
Gyorgy Csako MD FACP, Bethesda, MD, Chairman
Michael B Kays PharmD BCPS FCCP, Indianapolis, IN
William H Porter PhD, Lexington, KY
MANAGED CARE
Kristin R Gericke PharmD, Orange, CA, Chairman
Patrick P Gleason PharmD BCPS, St. Paul, MN
MEDICINE LAW AND ETHICS
Warren Richards PhD, West Palm Beach, FL, Chairman
William E Fassett MBA PhD, Pullman, WA
Jack E Fincham PhD, Lawrence, KS
Curtis Edward Harris MS MD JD, Ada, OK
NEONATOLOGY
Peter Gal PharmD BCPS FCCP FASHP, Greensboro, NC, Chairman
Varsha Bhatt-Mehta PharmD FCCP, Ann Arbor, MI
Bobby G Bryant MS PharmD, Ada, OH
Darlene A Calhoun DO, St. Petersburg, FL
Sherry A Luedtke PharmD, Amarillo, TX
NEPHROLOGY
Lori D Wazny PharmD, London, ON, Chairman
Thomas J Comstock PharmD, Richmond, VA
Suzette R Gendjar PharmD, Detroit, MI
Melanie S Joy PharmD, Chapel Hill, NC
Michael A Marx PharmD FCCP, Florence, KY
Bruce A Mueller PharmD FCCP, Ann Arbor, MI
Mary K Stamatakis PharmD, Morgantown, WV
NEUROLOGY
Melody Ryan PharmD, Lexington, KY, Chairman
Susan C Fagan PharmD FCCP, Augusta, GA
Barry E Gidal PharmD, Madison, WI
Gregory M Peterson PhD MBA FSHP FACPP,
Hobart, Tasmania, Australia
Mary L Wagner PharmD MS, Piscataway, NJ
NUCLEAR MEDICINE
Edward M Bednarczyk PharmD FCCP, Buffalo, NY, Chairman
David L Laven NPh CRPh FASHP FAPhA, Longwood, FL
NUTRITION SUPPORT AND PARENTERAL THERAPY
Paul G Cuddy PharmD, Kansas City, MO, Chairman
Christopher J Cairns BSc MSc FRPharmS, London, UK
Jay M Mirtallo BSPharm MS, Columbus, OH
OBESITY
Margaret Malone PhD FCCP, Albany, NY, Chairman
Liubov Louba Ben-Noun MD, Kiryat-Gat, Israel
ONCOLOGY
Mark T Holdsworth PharmD BCOP, Albuquerque, NM, Chairman
Linda R Bressler PharmD BCOP, Chicago, IL
Michael B Cockerham MS PharmD BCOP, Monroe, LA
Rebecca S Finley PharmD MS FASHP, Philadelphia, PA
Lea Ann Hansen PharmD BCOP, Richmond, VA
David R Kohler PharmD, Bethesda, MD
OPHTHALMOLOGY
Steven R Abel PharmD FASHP, Indianapolis, IN, Chairman
Rahamim Avisar MD, Petah-Tikva, Israel
Richard G Fiscella BSPharm MPH, Chicago, IL
Lois Ann Reynolds PharmD, Baltimore, MD
PAIN MANAGEMENT
Carlota O Andrews PhD PharmD, Erie, PA, Chairman
Betty J Chaffee PharmD, Livonia, MI
Barbara Kaplan-Machlis PharmD, Farmington Hills, MI
PEDIATRICS
John Erramouspe PharmD MS, Pocatello, ID, Chairman
Edward A Bell PharmD BCPS, Des Moines, IA
Olga Bessmertny PharmD, New York, NY
Marcia L Buck PharmD FCCP, Charlottesville, VA
Mark L Glover PharmD, Ft. Lauderdale, FL
Renee F Robinson PharmD, Columbus, OH
Marc G Sturgill PharmD, Piscataway, NJ
PHARMACEUTICAL EDUCATION
Stuart T Haines PharmD BCPS CACP, Baltimore, MD, Chairman
Stephen M Caiola MS, Chapel Hill, NC
Nancy F Fjortoft PhD, Downers Grove, IL
Kristin Kari Janke PhD, Minneapolis, MN
Bernard Sorofman PhD, Iowa City, IA
PHARMACODYNAMICS
Peter R Gwilt PhD, Omaha, NE, Chairman
Joseph O Olubadewo PhD, New Orleans, LA
PHARMACOECONOMICS AND OUTCOMES
Dennis W Raisch PhD, Albuquerque, NM, Chairman
J Lyle Bootman PhD, Tucson, AZ
Donald L Harrison PhD MS, Oklahoma City, OK
Alan H Mutnick PharmD FASHP, Iowa City, IA
Michael B Nichol PhD, Los Angeles, CA
Mark P Okamoto PharmD, Pomona, CA
Theresa I Shireman PhD, Lawrence, KS
Raymond J Townsend PharmD FCCP, Park City, UT
PHARMACOEPIDEMIOLOGY AND RISK MANAGEMENT
Hubert G M Leufkens PhD PharmD, Utrecht, Netherlands, Chairman
Darrel C Bjornson PhD, Goodyear, AZ
Thomas R Einarson PhD, Toronto, ON
Dag GL Isacson PhD MSc, Uppsala, Sweden
Marsha A Raebel PharmD BCPS, Denver, CO
Julie Magno Zito PhD, Baltimore, MD
PHARMACOGENETICS AND PHARMACOGENOMICS
Daniel S Streetman PharmD, Ann Arbor, MI, Chairman
Anthonius de Boer MD PhD, Utrecht, Netherlands
Ichiro Ieiri PhD, Yonago, Japan
J Steven Leeder PharmD PhD, Kansas City, MO
Jeannine S McCune PharmD BCPS BCOP, Seattle, WA
PHARMACOKINETICS
William R Ravis PhD, Auburn, AL, Chairman
Michael E Burton PharmD, Oklahoma City, OK
Mary HH Ensom PharmD FASHP FCCP FCSHP, Vancouver, BC
W Greg Leader PharmD, Monroe, LA
Jerome J Schentag PharmD, Buffalo, NY
PHARMACOMETRICS
Ene I Ette PhD FCP FCCP, Cambridge, MA, Chairman
Paul J Williams PharmD MS FCCP, Stockton, CA
PHARMACOSOCIOLOGY
Karen B Farris BSPharm PhD MPA, Iowa City, IA, Chairman
Michael Montagne PhD, Boston, MA
Bonnie L Svarstad PhD, Madison, WI
PREVENTIVE MEDICINE AND DISEASE STATE MANAGEMENT
Carol B Pugh PharmD, Richmond, VA, Chairman
Babette S Edgar PharmD BCPS, Hunt Valley, MD
Kathleen A Johnson PharmD MPH PhD, Los Angeles, CA
Linda K Ohri PharmD, Omaha, NE
PSYCHIATRY
Christopher P Alderman BPharm FSHP BCPP CGP, Adelaide, South Australia, Australia, Chairman
Charles F Caley PharmD BCPP, Storrs, CT
Marshall E Cates PharmD BCPP FASHP, Birmingham, AL
Louise Glassner Cohen PharmD BCPP, Boston, MA
M Lynn Crismon PharmD, Austin, TX
William J Docktor PharmD BCPS, Missoula, MT
Matthew A Fuller PharmD BCPS BCPP FASHP, Brecksville, OH
William A Kehoe Jr PharmD MA FCCP BCPS, Stockton, CA
Gary M Levin PharmD BCPP FCCP, Savannah, GA
Ian D Maidment BPharm MRPharmS, Canterbury, Kent, UK
Ole J Thienhaus MBA MD FACP, Las Vegas, NV
PULMONARY
Karen J Tietze BSPharm PharmD, Philadelphia, PA, Chairman
Roy A Pleasants PharmD BCPS, Durham, NC
Theresa R Prosser PharmD FCCP BCPS AE-C, St. Louis, MO
QUALITY OF LIFE
Steven R Erickson PharmD, Ann Arbor, MI, Chairman
Jane T Osterhaus PhD, Park City, UT
Norma Stava Robinson BSPharm PharmD, Emporia, KS
RESEARCH DESIGN AND STATISTICS
Wesley G Byerly PharmD, Winston-Salem, NC, Chairman
Joseph A Grillo PharmD, Rockville, MD
John R Hayes PhD, Columbus, OH
Kate L Lapane PhD, Providence, RI
Kenneth A Lawson PhD, Austin, TX
RHEUMATOLOGY
Frank Pucino PharmD BCPS, Bethesda, MD, Chairman
Eric G Boyce PharmD, Wingate, NC
Margaret Noyes Essex PharmD BCPS, Fairfield, CT
Beth H Resman-Targoff PharmD, Oklahoma City, OK
STDs AND HIV/AIDS
Patrick G Clay PharmD, Kansas City, MO, Chairman
Betty J Dong PharmD, San Francisco, CA
Douglas N Fish PharmD BCPS, Denver, CO
Alice K Pau PharmD, Bethesda, MD
Helene Peyriere PharmD PhD, Montpellier, France
Ralph H Raasch PharmD FCCP BCPS, Chapel Hill, NC
Frank Romanelli PharmD BCPS, Lexington, KY
Gary H Smith PharmD FASHP FCCP, Baltimore, MD
Suellyn J Sorensen PharmD BCPS, Indianapolis, IN
Alice Lin-in Tseng PharmD FCSHP, Toronto, ON
THERAPEUTIC MONITORING
Richard L Slaughter MS FCCP, Detroit, MI, Chairman
Kevin T Batty PhD, Perth, Western Australia, Australia
Paul M Beringer PharmD BCPS, Los Angeles, CA
Martin Schulz PhD, Berlin, Germany
TOXICOLOGY AND POISON CONTROL
Elizabeth J Scharman PharmD DABAT BCPS, Charleston, WV, Chairman
Peter A Chyka PharmD, Memphis, TN
Wendy Klein-Schwartz PharmD MPH, Baltimore, MD
John Greene Shepherd PharmD, Dallas, TX
TRANSPLANTATION
Robert E Dupuis PharmD BCPS, Chapel Hill, NC, Chairman
David I Min PharmD FCCP, Iowa City, IA
Jennifer Trofe BSPharm PharmD BCPS, Cincinnati, OH
WOMEN'S HEALTH
Candace S Brown PharmD FNP, Memphis, TN, Chairman
Gerald G Briggs BPharm, Long Beach, CA
Thomas ER Brown PharmD, Toronto, ON
Publisher and Editor
Harvey AK Whitney Jr MSPharm
|
Senior Editor
Milap C Nahata MS PharmD
|
Senior Production Editor
Stephanie M Lang |
Author Services Assistant
Maria R Guajardo |
Associate Editor and Director of Operations
Eugene M Sorkin PharmD
|
Production Editor
William J Grapes |
Publisher's Assistant
Deborah S Hyrne |
Assistant Editor and Director of Professional Services
Stanley J Lloyd
|
Manuscripts Editor
AnnElise Makin |
Assistant to the Editor
April Salyers |
Editor at Large and Director of Continuing Education
Timothy E Welty PharmD BCPS
|
Editorial Production Assistant
Peggy H McDaniel |
Circulation Manager
Ann Brandewiede |
Executive Director of Editorial Services
Jerome P Rosenthal PhD
|
Director of Electronic Media
Kim E Whitney |
Advertising and Marketing Manager
Greg J Johnson |
Editorial Coordinator
Donna J Thordsen
|
Electronic Media Manager
Sarah C Schroer |
Business Manager
Tina Whitney |
|
Author Services Manager
LizAnne Sawyer-Kubicki
|
|
